SCHEMBL5224593

SCHEMBL5224593

O=C1CCN(C(=O)O)C(C(=O)O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223810 1.00
SCHEMBL15542290 1.00
SCHEMBL20723785 0.82 ALDH1A1 (0.35)
SCHEMBL20723786 0.82 ALDH1A1 (0.35)
SCHEMBL4418517 0.80 MMP2 (0.46)
SCHEMBL30346218 0.80 TSHR (0.39)
SCHEMBL22518861 0.80
SCHEMBL22518860 0.80
SCHEMBL1250785 0.79 MMP2 (0.36)
SCHEMBL6921106 0.79 MMP2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
EP-4065113-B1 (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION Rottapharm Biotech Srl (IT) 2024-01-10 EP disclosed
US-20230357271-A1 MACROCYCLIC COMPOUND ASAHI KASEI PHARMA CORPORATION (JP) 2023-11-09 US disclosed
EP-4223368-A1 MACROCYCLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2023-08-09 EP disclosed
US-20230234958-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF D. E. SHAW RESEARCH, LLC 2023-07-27 US disclosed
WO-2023137225-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2023-07-20 WO disclosed
US-11685746-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-06-27 US disclosed
US-11590114-B2 Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours ROTTAPHARM BIOTECH S.R.L. (IT) 2023-02-28 US disclosed
US-20230028519-A1 (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION ROTTAPHARM BIOTECH S.R.L. (IT) 2023-01-26 US disclosed
US-20220340576-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2022-10-27 US disclosed
CN-104940202-B Inhibitors of influenza viruses replication 沃泰克斯药物股份有限公司 2018-10-16 CN disclosed
WO-2018115275-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION IRBM SCIENCE PARK S.P.A. (IT) 2018-06-28 WO disclosed
US-20180162855-A1 PDD AND BPD COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2018-06-14 US disclosed
CN-104151312-B Inhibitors of influenza viruses replication 沃泰克斯药物股份有限公司 2016-06-15 CN disclosed
CN-104940202-A Inhibitors of influenza viruses replication VERTEX PHARMA 2015-09-30 CN disclosed
CN-104922128-A INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMA 2015-09-23 CN disclosed
CN-102458408-B Inhibitors of influenza virus replication VERTEX PHARMA 2015-06-03 CN disclosed
CN-102458408-A Inhibitors of influenza virus replication VERTEX PHARMA 2012-05-16 CN disclosed
EP-1814893-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2007-08-08 EP disclosed
WO-2006055070-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2006-05-26 WO disclosed